IV 

111TH CONGRESS 

1ST SESSION H. RES. 906 

Expressing the sense of the House of Representatives to encourage continued 

investment to complete the development of an HIV/AIDS vaccine for 

the United States. 

IN THE HOUSE OF REPRESENTATIVES 

NOVEMBER 16, 2009 

Mr. LEWIS of Georgia (for himself, Mr. JOHNSON of Georgia, and Mr. 

GRIJALVA) submitted the following resolution; which was referred to the 

Committee on Energy and Commerce 

RESOLUTION 

Expressing the sense of the House of Representatives to 

encourage continued investment to complete the development of an HIV/AIDS vaccine for the United States. 

Whereas HIV affects the entire globe and comes in a variety 

of subtypes; 

Whereas the United States is leading global efforts to combat 

the HIV/AIDS pandemic through its $15,000,000,000 

Global Fund to Fight AIDS, Tuberculosis and Malaria, 

which do not address the United States strain of the 

virus, Clade B; 

Whereas Clade B is the predominant subtype in the United 

States where the estimated number of new HIV infections in adults and adolescents in 2006 was 56,300, the 


wwoods2 on DSK1DXX6B1PROD with BILLS
2 

•HRES 906 IH 

overall rate of new HIV infections was 22.8 cases per 

100,000 population; 

Whereas in 2007, the estimated rate of people who have progressed from HIV to AIDS in the United States was 

11.9 cases per 100,000 population; 

Whereas from 2004 through 2007, the estimated number of 

newly diagnosed HIV/AIDS cases in the United States 

increased among all races and ethnicities, with AfricanAmericans accounting for 51 percent of all new HIV/ 

AIDS cases diagnosed in 2007; 

Whereas from 2004 through 2007, the estimated number of 

newly diagnosed HIV/AIDS cases increased approximately 18 percent among males and 8 percent among females, and males accounted for 74 percent of all HIV/ 

AIDS cases among adults and adolescents in 2007; 

Whereas of the HIV infections diagnosed in 2006 in the 34 

States with confidential name-based HIV reporting, 36 

percent progressed to AIDS within 12 months after the 

HIV infection was diagnosed; 

Whereas at the end of 2007, the AIDS prevalence rate 

among adults and adolescents in the United States was 

estimated at 185.1 per 100,000 with the highest prevalence rate in Washington, DC, estimated at 1,750.6 per 

100,000 population; 

Whereas through 2007, a total of 1,030,832 persons in the 

United States and dependent areas had been reported as 

having AIDS since the epidemic began; 

Whereas each year, more than 14,000 people with AIDS die 

in the United States; 


wwoods2 on DSK1DXX6B1PROD with BILLS
3 

•HRES 906 IH 

Whereas President Obama has pledged to develop and implement a comprehensive national HIV/AIDS strategy that 

will include a focus on reducing HIV incidence; 

Whereas there are few alternatives for preventing HIV transmission other than abstinence, education, circumcision, 

and condoms; 

Whereas in 2002, the total aggregate lifetime cost of illness 

for people in the United States newly diagnosed with 

HIV was estimated to be $36,400,000,000; 

Whereas it is estimated that patients on antiretroviral therapy have direct, individual medical costs averaging 

$230,044, based on an estimated life expectancy of 24.4 

years after diagnosis; 

Whereas in FY 2007, alone, the cost to the Federal Government for programs to care for people living with HIV/ 

AIDS in the United States was $13,200,000,000; 

Whereas as with commonly used vaccines such as polio, if the 

population were vaccinated for HIV, over time, the disease would decrease in prevalence to the point where it 

could be essentially eradicated; 

Whereas an HIV vaccine could be used to protect individuals 

from developing AIDS or used to treat people already infected with HIV to prevent the disease from progressing 

to AIDS; 

Whereas there are three HIV/AIDS vaccines, out of approximately 100 original vaccine candidates that were part of 

the Phase 1 protocols undertaken by the NIH-funded 

HIV Vaccine Trials Network (HVTN) that are presently 

in clinical testing at the Phase 2 level and beyond; 

Whereas two of the vaccines that were part of the Phase 1 

protocols undertaken by HVTN are viable candidates for 


wwoods2 on DSK1DXX6B1PROD with BILLS
4 

•HRES 906 IH 

preventing the United States strain of HIV infection 

from progressing to AIDS; 

Whereas in 2009, the results of a clinical trial conducted in 

Thailand indicated that an AIDS vaccine was safe and 

reduced the chance of infection by 31 percent; and 

Whereas despite the failure of other HIV/AIDS vaccines, the 

testing of the remaining two vaccines which hold promise 

for preventing the United States strain of the AIDS virus 

should be encouraged by public and private sectors: Now, 

therefore, be it 

1 Resolved, That the House of Representatives strongly 

2 encourages domestic efforts in the public and private sec3 tors to invest in and complete the development of a vaccine 

4 for the United States strain of the HIV/AIDS virus, Clade 

5 B. 

Æ 


wwoods2 on DSK1DXX6B1PROD with BILLS